What Are ORACEA Capsules?

ORACEA Capsules are a convenient, once-daily treatment for the bumps and blemishes of rosacea Learn More

Save on ORACEA Capsules

Find out how you may be able to save on your prescriptions
Learn More

Break Up With Your Makeup Contest

Important Safety Information

Indication: ORACEA® (doxycycline, USP) 40 mg* Capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. ORACEA Capsules do not lessen the facial redness caused by rosacea. Adverse Events: In controlled clinical studies, the most commonly reported adverse events (>2%) in patients treated with ORACEA Capsules were nasopharyngitis, sinusitis, diarrhea, hypertension and aspartate aminotransferase increase. Warnings/Precautions: ORACEA Capsules should not be used to treat or prevent infections. ORACEA Capsules should not be taken by patients who have a known hypersensitivity to doxycycline or other tetracyclines. ORACEA Capsules should not be taken during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years). Although photosensitivity was not observed in clinical trials, ORACEA Capsules patients should minimize or avoid exposure to natural or artificial sunlight. The efficacy of ORACEA Capsules treatment beyond 16 weeks and safety beyond 9 months have not been established.

*30 mg immediate release & 10 mg delayed release beads

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For insured patients only. Certain limitations apply. Click here for program details.

Program details for all savings offers

ORACEA® (OR-RAY-SHA) Program details for all saving offers

For insured patients only.

OFFER NOT AVAILABLE FOR UNINSURED OR CASH PATIENTS
1. This offer is not valid if prescriptions are paid by Medicare Part D, Medicaid, Medigap, VA, DoD, TRICARE, or any other government-run or government-sponsored health care program with a pharmacy benefit. 2. This card may not be combined with any savings, discount, free trial, or other similar offer for the same prescription. 3. This offer is not transferable and void if reproduced. 4. This offer is not health insurance. 5. Limit one (1) card per patient. 6. This card has no cash value and will not be accepted outside of participating pharmacies in the United States. 7. GALDERMA RESERVES THE RIGHT TO RESCIND, REVOKE OR AMEND THIS OFFER AT ANY TIME. 8. Galderma will deny payment for noncompliance with the terms of this offer. 9. This offer expires no later than December 31, 2016. 10. This offer may be subject to limitations imposed by state or federal law or by your health insurer and this offer is not valid where prohibited by law or by your health insurer.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Other program information:

  • Effective September 2015, the ORACEA Care Card will have a maximum benefit of $450.
  • Effective September 2015, the ORACEA Patient Savings Card will have a maximum benefit of $450.
  • Effective September 2015, the ORACEA Instant Savings Card will be limited to 4 fills and will have a maximum benefit of $450.
Oracea Logo

Important Safety Information

Indication: ORACEA® (doxycycline, USP) 40 mg* Capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. ORACEA Capsules do not lessen the facial redness caused by rosacea. Adverse Events: In controlled clinical studies, the most commonly reported adverse events (>2%) in patients treated with ORACEA Capsules were nasopharyngitis, sinusitis, diarrhea, hypertension and aspartate aminotransferase increase. Warnings/Precautions: ORACEA Capsules should not be used to treat or prevent infections. ORACEA Capsules should not be taken by patients who have a known hypersensitivity to doxycycline or other tetracyclines. ORACEA Capsules should not be taken during pregnancy, by nursing mothers, or during tooth development (up to the age of 8 years). Although photosensitivity was not observed in clinical trials, ORACEA Capsules patients should minimize or avoid exposure to natural or artificial sunlight. The efficacy of ORACEA Capsules treatment beyond 16 weeks and safety beyond 9 months have not been established.

*30 mg immediate release & 10 mg delayed release beads